Atorvastatin calcium: CONCLUSIONS(1)
Other studies evaluating costs associated with atorvasta-tin treatment are underway. As discussed earlier, several long term studies are in progress evaluating outcomes in cardiovascular events (such as incidence rates of cardiac death, non-fatal MI and surgical procedures), and these studies will also include economic assessments.
There is ample and incontrovertible evidence demonstrating that reduced cholesterol levels are associated with a reduced risk of future cardiovascular events. Regardless of the intervention used (low fat and low cholesterol diet, partial ileal bypass surgery, pharmacological therapy), effective treatment of elevated cholesterol levels has consistently been shown to reduce the risk of CAD. LDL-C is recognized as the major atherogenic lipoprotein fraction in the development of atherosclerosis. Recent studies with HMG-CoA reductase inhibitors have shown that lowering LDL-C (and total cholesterol) levels significantly reduces the risk of developing cardiovascular events and the incidence of cardiovascular death and total mortality. ventolin inhaler
Atorvastatin calcium is a new, synthetic HMG-CoA reductase inhibitor approved for use in Canada for the treatment of dyslipidemic conditions. Clinical trial results indicate that atorvastatin is the most efficacious of the HMG-CoA reductase inhibitor class of lipid-lowering agents in reducing elevated levels of plasma LDL-C. In addition, atorvastatin substantially lowers elevated plasma triglyceride levels. Mechanism of action studies suggest that the efficacy of ator-vastatin is due to a more prolonged and sustained inhibition of HMG-CoA reductase and to inhibition of the production of apo B-containing lipoproteins (VLDL and LDL particles).